Back

Medscape, LLC

  • Myasthenia Gravis

Time Matters in Generalized Myasthenia Gravis: Improving Timely Access to Targeted Therapies

The goal of this activity is for learners to be better able to utilize US Food and Drug Administration (FDA)-approved targeted therapies for generalized MG (gMG) in a timely manner and in a way that maximizes efficacy and safety.

Credit & MOC Details

Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.

Credit types

AMA PRA Category 1 Credit™Up to 0.75 creditsNursingUp to 0.75 credits

MOC types

ABIM — Medical KnowledgeUp to 0.75 points

FDA REMS

No

Qualifies for MIPS

No

Pricing

Free

Reported to ACCME by the provider

  • Enduring / On-demand
  • Credit · Up to 0.75 credits
  • MOC · Up to 0.75 points
  • Commercial Support
  • Released
    Nov 20, 2025
  • Last day to claim credit
    Nov 21, 2026 6 weeks left